<DOC>
	<DOC>NCT02755974</DOC>
	<brief_summary>The London COPD exacerbation (EXCEL) cohort builds on an established cohort started in 1995 and designed to study COPD exacerbations and their impact on health-status and disease progression.</brief_summary>
	<brief_title>The London COPD Exacerbation Cohort</brief_title>
	<detailed_description>Our intentions are to phenotype Chronic Obstructive Pulmonary Disease (COPD) patients on the basis of factors that a related to (a) exacerbation frequency which will include (b) lung function to assess disease severity, (c) baseline therapy, (d) airway and systemic inflammatory markers, (e) health status, (f) gene expression, (g) airway bacterial and viral load and (h) co-morbidity including cardiovascular disease, diabetes and psychological disease, (i) psychological factors,(j) mortality, (k) nasal susceptibility to rhinovirus infection, (l) heart rate variability (m) exhaled hydrogen sulphide.</detailed_description>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
	<criteria>Forced Expiratory Volume in 1 sec (FEV1)/Forced Vital Capacity (FVC) ratio of &lt;0.70 Able and willing to give informed and written consent Patients with a history of asthma, bronchiectasis, carcinoma of the bronchus, or other significant respiratory disease were excluded. Patients on Immunosuppressive medications or with active cancer Long term steroid therapy Age &lt;40 years at recruitment</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>100 Years</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>